ZURICH (Reuters) - Novartis drug Afinitor, expected to become a major seller for the Swiss drugmaker, was approved by European regulators to treat women with a certain type of breast cancer, the company said on Monday. The drug is the first in a class known as mTOR inhibitors to be approved for post-menopausal women with advanced hormone-receptor positive, HER2-negative breast cancer. American health regulators also backed the drug as a breast cancer treatment. ... read more..
Monday, 30 July 2012
Breast Cancer Treatment-European Regulators-Mtor Inhibitors-Novartis
Sunday, 1 July 2012
Cost Body Backs Novartis-National Institute-Multiple Sclerosis-Pill Gilenya-Novartis Ag
LONDON (Reuters) - Novartis's multiple sclerosis pill Gilenya, one of its top new drug hopes, has been recommended for use in the state health service after a change of heart by the country's healthcare cost-effectiveness watchdog. Friday's verdict from the National Institute for Health and Clinical Excellence (NICE), whose opinions are also watched closely in other countries, is welcome news for a product that has run into problems recently. ... read more..
Thursday, 14 June 2012
Novartis Consumer Health-Office Workers-Healthday News
ZURICH (Reuters) - Novartis's consumer health unit will take a $120 million hit in the fourth quarter after the Swiss drugmaker decided to voluntarily recall some products in the United States and move to improve quality standards at manufacturing sites. Novartis said in a statement on Sunday that operations and shipments had been temporarily stopped at the Novartis Consumer Health (NCH) Lincoln, Nebraska facility, to accelerate improvements at the site. ... read more..
Being bored at work can be really, really bad for your health! http://ow.ly/8tlal
Being bored at work can be really, really bad for your health! http://ow.ly/8tlalBored Workers Often Turn to Chocolate, Booze, Study Finds - Health News...ow.lyFRIDAY, Jan. 13 (Healthday News) — Chronic boredom grips one-fourth of office workers, which may affect their quality of work as well as their... read more..
Wednesday, 25 April 2012
Drugmaker Novartis Ag-Stoppage
ZURICH (Reuters) - Swiss drugmaker Novartis AG on Tuesday stuck to its outlook for lower profitability this year, as a stoppage at a U.S. manufacturing site and tough annual comparisons for its Sandoz division hit first-quarter core earnings. Chief Executive Joseph Jimenez said he expected production at a consumer health manufacturing site in Lincoln, Nebraska - which has annualized sales of $1 billion - to restart in May, with shipments resuming mid-year. The stoppage to sort out quality issues sent net sales in the consumer health division down 20 percent in the first quarter. ... read more..
Friday, 23 March 2012
Food And Drug Administration-Novartis
The U.S. Food And Drug Administration is warning patients about a potential mix-up between powerful prescription pain drugs and common over-the-counter medications made at a Novartis manufacturing plant. read more..